Sidjanin, Duska J., McCarty, Catherine A., Patchett, Richard, Smith, Edward M. and Wilke, Russell A.. (2008) Pharmacogenetics of ophthalmic topical β-blockers. Personalized Medicine, Vol.5 (No.4). pp. 377-385. ISSN 1741-0541

PDF WRAP_Smith_bs-031110-sidjanin_et_al_2008open.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (795Kb)

Abstract

Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical β-blockers. This review summarizes clinically significant polymorphisms that have been identified in the β-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basis of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical β-blockers may advance individualized treatment at a lower cost.

Item Type:	Journal Article
Subjects:	R Medicine > RE Ophthalmology
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Glaucoma -- Genetic aspects, Adrenergic beta blockers, Beta adrenoceptors, Genetic polymorphisms
Journal or Publication Title:	Personalized Medicine
Publisher:	Future Medicine Ltd.
ISSN:	1741-0541
Date:	July 2008
Volume:	Vol.5
Number:	No.4
Page Range:	pp. 377-385
Identification Number:	10.2217/17410541.5.4.377
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	Medical College of Wisconsin. Dept. of Ophthalmology, American Health Assistance Foundation
References:	1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2002;82:844–851. [PubMed: 15640920] 2. Friedman DS, Wolfs C, O’Colmain BJ, et al. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–538. [PubMed: 15078671]• Combines data from a number of population-based epidemiologic studies to calculate estimates of the number of individuals affected by glaucoma in the USA. 3. Foster PJ. The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. Semin Ophthalmol 2002;17:50–58. [PubMed: 15513457] 4. Sowka J. New thoughts on normal tension glaucoma. Optometry 2005;76:600–608. [PubMed: 16230276] 5. Alward WL. Medical management of glaucoma. N Engl J Med 1998;29:1298–1307. [PubMed: 9791148] 6. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet 1997;6:641–647. [PubMed: 9097971] 7. Idrees F, Vaideanu D, Fraser SG, Sowden JC, Khaw PT. A review of anterior segment dysgeneses. Surv Ophthalmol 2006;51:213–231. [PubMed: 16644364] 8. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668–670. [PubMed: 9005853] 9. Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S. Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. Am J Hum Genet 1997;61:1202–1204. [PubMed: 9345106] 10. Wiggs JL, Vollrath D. Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. Arch Ophthalmol 2001;119:1674–1678. [PubMed: 11709019] 11. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077–1079. [PubMed: 11834836] 12. Monemi S, Spaeth G, DaSilva A, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet 2005;14:725–733. [PubMed: 15677485] 13. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991;98:301–307. [PubMed: 2023749] 14. Fleming C, Whitlock EP, Beil T, Smit B, Harris RP. Screening for primary open-angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. Ann Fam Med 2005;3:167–170. [PubMed: 15798044] 15. American Academy of Ophthalmology. Preferred Practice Pattern for Primary Open-Angle Glaucoma. AAO; CA, USA: 2005. 16. Papadopoulos M, Khaw PT. Advances in the management of paediatric glaucoma. Eye 2007;21:1319– 1325. [PubMed: 17914435] 17. Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol 2002;47:S129–S132. [PubMed: 12204709] 18. Shin J, Johnson JA. Pharmacogenetics of β-blockers. Pharmacotherapy 2007;27:874–887. [PubMed: 17542770] 19. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59:411–434. [PubMed: 10776828] 20. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978;96:2045–2048. [PubMed: 363105] 21. Zimmerman TJ, Harbin R, Pett M, Kaufman HE. Timolol and facility of outflow. Invest Ophthalmol Vis Sci 1977;16:623–624. [PubMed: 873723] 22. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Invest Ophthalmol Vis Sci 1978;17:293–296. [PubMed: 627467] 23. Zimmerman TJ, Boger WP. The β-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol 1979;23:347–362. [PubMed: 37605] 24. Higginbotham EJ, Schuman JS, Goldberg I, et al. Bimatoprost study groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286–1293. [PubMed: 12365906] 25. Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2002;132:472–484. [PubMed: 11589866] 26. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 2003;3:197–201. [PubMed: 12931133] 27. Nieminen T, Lehtimaki T, Maenpaa J, Ropo A, Uusitalo H, Kahonen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237–245. [PubMed: 17366003] 28. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104:197–199. [PubMed: 3946944] 29. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol 1986;15:606–611. [PubMed: 3777080] 30. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736–738. [PubMed: 507146] 31. van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980;87:447–450. [PubMed: 7402590] 32. Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol maleate on tear flow in human eyes. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980;213:19–22. [PubMed: 6906142] 33. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003;136:18–25. [PubMed: 12834665] 34. Stewart WC, Sine C, Cate E, Minno GE, Hunt H. Daily cost of β-adrenergic therapy. Arch Ophthalmol 1987;115:853–856. [PubMed: 9230824] 35. Sorensen SJ, Abel SR. Comparison of ocular β-blockers. Ann Pharmacother 1996;30:43–54. [PubMed: 8773166] 36. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119–137. [PubMed: 16409140] 37. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464–468. [PubMed: 15164072] 38. Wax MB, Molinoff PB. Distribution and properties of β-adrenergic receptors in human iris–ciliary body. Invest Ophthalmol Vis Sci 1987;28:420–430. [PubMed: 3030954] 39. Taylor MRG. Pharmacogenetics of the human β-adrenergic receptors. Pharmacogenomics J 2007;7:29–37. [PubMed: 16636683] 40. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac β(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 1999;14:271. [PubMed: 10477438] 41. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem 1999;274:12670–12674. [PubMed: 10212248] 42. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002;277:30429–30435. [PubMed: 12034720] 43. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human β 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414–9419. [PubMed: 7915137] 44. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. β 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003;9:1300–1305. [PubMed: 14502278] 45. Iwai C, Akita H, Kanazawa K, et al. Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003;146:106–109. [PubMed: 12851615] 46. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the β 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635–1641. [PubMed: 7706471] 47. Timmermann B, Mo R, Luft FC, et al. β-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int 1998;53:1455–1460. [PubMed: 9607174] 48. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 2005;294:1526–1533. [PubMed: 16189366] 49. del Moral R, Lopez ME, Nunez MI, et al. Interactions between radiotherapy and endocrine therapy in breast cancer. Endocr Relat Cancer 2002;9:197–205. [PubMed: 12237247] 50. Terra SG, McGorray SP, Wu R, et al. Association between β-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes 2005;29:746–754. 51. Miyaki K, Sutani S, Kikuchi H, et al. Increased risk of obesity resulting from the interaction between high energy intake and the Trp64Arg polymorphism of the β3-adrenergic receptor gene in healthy Japanese men. J Epidemiol 2005;15:203–210. [PubMed: 16276029] 52. Hao K, Peng S, Xing H, et al. β(3) adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients. Obes Res 2004;12:125–130. [PubMed: 14742851] 53. Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. β1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology 2005;112:2131–2136. [PubMed: 16325708] 54. Nieminen T, Uusitalo H, Maenpaa J, et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 2005;61:811–819. [PubMed: 16315032]• One of the first studies to look at CYP2D6 polymorphisms in glaucoma therapy. 55. McCarty CA, Wilke RA, Giampietro PF, Wesbrook S, Caldwell MD. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large, population-based biobank. Personalized Medicine 2005;2:49–79. 56. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA. Pressure response to topical β- blockers is associated with an ADRB2 SNP. Arch Ophthalmol. 2008In Press•• Recent study quantifying the role of ADRB polymorphisms in glaucoma therapy. 57. Inagaki Y, Mashima Y, Fuse N, et al. Polymorphism of β-adrenergic receptors and susceptibility to open-angle glaucoma. Mol Vis 2006;12:673–680. [PubMed: 16785856] 58. Gungor K, Beydagi H, Bekir N, et al. The impact of acute dynamic exercise on intraocular pressure: role of the β 2-adrenergic receptor polymorphism. J Int Med Res 2002;30:26–33. [PubMed: 11921496] 59. McLaren N, Reed DM, Musch DC, et al. Evaluation of the β2-adrenergic receptor gene as a candidate glaucoma gene in 2 ancestral populations. Arch Ophthalmol 2007;125:105–111. [PubMed: 17210860] 60. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004;76:302–312. [PubMed: 15470329] 61. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465–472. [PubMed: 12172215] 62. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. Potential for oral–ophthalmic drug interaction. JAMA 1995;274:1611–1613. [PubMed: 7474246] 63. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Opthalmol 2006;90:262–267. 64. Wilke RA, Reif DG, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005;4:911– 918. [PubMed: 16264434] 65. Wilke RA, Mareedu R, Moore JH. The pathway less traveled: moving toward candidate genes and candidate pathways in the analysis of genome wide data from large-scale pharmacogenetic association studies. Curr Pharmacogenomics Personalized Med. 2008In Press• An approach using pathway-based data to inform the analysis of genome scans. 101. OMIMwww.ncbi.nlm.nih.gov/sites/entrez?db=OMIM&itool=toolbar 102. SOURCE (unification tool) 2007 http://smd.stanford.edu/cgi-bin/source/ sourceSearch 103. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.imm.ki.se/CYPalleles/cyp2d6.htm
URI:	http://wrap.warwick.ac.uk/id/eprint/3628

Request changes to a record

Actions (login required)

View Item